Eli Lilly Stock Plummets 20.55% in Trading Volume Ranking 28th Amid Verve Therapeutics Acquisition

On June 17, 2025, Eli Lilly (LLY) experienced a significant decline in its stock price, with a trading volume of 18.25 billion, marking a 20.55% decrease from the previous day. This decline placed Eli Lilly at the 28th position in terms of trading volume for the day. The stock has been on a downward trend, falling 2.02% over the past two days, resulting in a cumulative drop of 3.43%.

Eli Lilly has announced its acquisition of Verve Therapeutics, a gene-editing company, for up to $1.3 billion. This strategic move aims to advance one-time treatments for individuals at high risk of cardiovascular disease. The deal includes an upfront payment of nearly $1 billion, with an additional $300 million contingent on Verve achieving specific clinical milestones. Verve Therapeutics is currently conducting an early-stage clinical trial for a treatment designed to lower cholesterol and address cardiovascular conditions. The acquisition is expected to close in the third quarter of this year.

Eli Lilly's decision to acquire Verve Therapeutics underscores its commitment to innovation in gene editing and cardiovascular care. The acquisition is part of a broader strategy to enhance its portfolio of genetic medicines and treatments. Verve Therapeutics, founded with the mission to transform cardiovascular disease treatment, has made significant progress in developing gene-editing products, with two currently in clinical trials. The company's CEO, Dr. Sekar Kathiresan, expressed excitement about the partnership, highlighting the potential to accelerate drug development with Lilly's support.